April 2012

September 2008 international clinical trial update

United States

IPI-504 Phase III: The first open site for the IPI-504 Phase III trial has been reported at Park Ridge, IL. Please contact the GIST Phase 3 Team at 877-504- INFI or This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

IPI-493 Phase I: Infinity has announced the opening of a Phase I trial for IPI-493 an oral HSP-90 inhibitor. The goal of the trial is to determine the safety and maximum tolerable dose and to determine a dosing schedule for future trials. The trial is open to patients with advanced malignancies who are progressing. Patients who have had prior HSP-90 therapy appear to be excluded. Concurrent use of tyrosine kinase therapy (Gleevec, Sutent, Tasigna) appears also to not be allowed. There is a long list of specific exclusions that can be reviewed at clinicaltrials. gov by searching for the NCT # 00724425 and/or by calling the site contacts. The trial is reportedly open at two locations in California: Premiere Oncology in Santa Monica, Calif. Contact Marilyn Mulay at 310-633-8400 or This e-mail address is being protected from spambots. You need JavaScript enabled to view it . The other site is San Diego Pacific Oncology and Hematology Associates in Encinitas, Calif. Contact Karen Brady at 760-752-3340 or kbrady@premiere oncology.com.

PX-866 Phase I: ProIX has initiated a phase I trial of an oral PI3K inhibitor PX-866 for advanced solid tumors. The trial is listed as currently recruiting at two sites: University of Colorado Health Sciences Center in Aurora, Colo. Contact Sharon Hecker at 720-848-0667 or This e-mail address is being protected from spambots. You need JavaScript enabled to view it . Also MD Anderson Cancer Center in Houston, Texas. Contact Rhonda Clement at 713- 563-3559 or This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

International

LBH589 Phase I & Dasatinib Phase I: These two trials, both only in Japan, are now listed as no longer recruiting and have been removed from the list.

Imatinib or Sunitinib Phase III: This trial has added new sites in Italy, Spain and the United Kingdom.

AUY922 Phase I & BGT226 Phase I: These two trials have been recruiting in the US and now have now added sites in Switzerland and Spain respectively.